

Randox STI assay gets CE mark

March 6, 2020—[Randox](#) announced that its Randox STI assay has received the CE mark. The multiplex assay detects 10 STIs, including co-infections, from a single patient sample. It tests simultaneously for *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Trichomonas vaginalis*, *Mycoplasma genitalium*, *Treponema pallidum*, HSV-1, HSV-2, *Haemophilus ducreyi*, *Mycoplasma hominis*, and *Ureaplasma urealyticum*.

“Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. The CE marking of the STI assay, which incorporates Randox biochip technology, will be a game-changer for clinicians and patients across Europe by facilitating early, accurate, and comprehensive diagnoses of STIs that allows for the best possible patient outcome,” Peter FitzGerald, managing director of Randox Laboratories, said in a press statement.

The Randox STI assay is performed on the Vivalytic system, a point-of-care platform developed in partnership with Bosch.